Does dual therapy with dabigatran and a P2Y12 inhibitor reduce the risk of bleeding in patients with atrial fibrillation who had undergone PCI?
In patients with atrial fibrillation undergoing PCI, dual antithrombotic therapy with dabigatran reduces bleeding risk compared to triple therapy with warfarin, without compromising protection against thromboembolic events.
Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y12 inhibitor than among those who received triple therapy with warfarin, a P2Y12 inhibitor, and aspirin. Dual therapy was noninferior to triple therapy with respect to the risk of thromboembolic events. (Funded by Boehringer Ingelheim; RE-DUAL PCI ClinicalTrials.gov number, NCT02164864 .).
Cannon et al. (Sun,) studied this question.